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Tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS) is a 
rare monogenic autoinflammatory disorder characterized by mutations in the TNFRSF1A 
gene, causing TNF-receptor 1 (TNFR1) misfolding, increased cellular stress, activation 
of the unfolded protein response (UPR), and hyperresponsiveness to lipopolysaccharide 
(LPS). Both microRNA (miR)-146a and miR-155 provide negative feedback for LPS-toll-
like receptor 2/4 signaling and cytokine production, through regulation of nuclear factor 
kappa B (NF-κB). In this study, we hypothesized that proinflammatory cytokine signaling 
in TRAPS downregulates these two miRs, resulting in LPS-induced hyperresponsive-
ness in TRAPS dermal fibroblasts (DFs), irrespective of the underlying genetic mutation. 
Primary DF were isolated from skin biopsies of TRAPS patients and healthy controls 
(HC). TNFR1 cell surface expression was measured using immunofluorescence. DF were 
stimulated with LPS, interleukin (IL)-1β, thapsigargin, or TNF, with and without inositol- 
requiring enzyme 1 (IRE1) inhibitor (4u8C), following which miR-146a and miR-155 
expression was measured by RT-qPCR. IL-1β, IL-6, and TNF secretion was measured 
by enzyme-linked immunosorbent assays, and baseline expression of 384 different miRs 
was assessed using microfluidics assays. TNFR1 was found to be expressed on the 
surface of HC DF but expression was deficient in all samples with TRAPS-associated 
mutations. HC DF showed significant dose-dependent increases in both miR-146a and 
miR-155 expression levels in response to LPS; however, TRAPS DF failed to upregulate 
either miR-146a or miR-155 under the same conditions. This lack of miR-146a and miR-
155 upregulation was associated with increased proinflammatory cytokine production in 
TRAPS DF in response to LPS challenge, which was abrogated by 4u8C. Incubation of 
HC DF with IL-1β led to downregulation of miR-146a and miR-155 expression, which 
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was dependent on IRE1 enzyme. We observed global dysregulation of hundreds of 
other miRs at baseline in the TRAPS DF. In summary, these data suggest a mechanism 
whereby IL-1β, produced in response to activation of the UPR in TRAPS DF, downregu-
lates miR-146a and miR-155, by inducing IRE1-dependent cleavage of both these miRs, 
thereby impairing negative regulation of NF-κB and increasing proinflammatory cytokine 
production.
Keywords: tumor necrosis factor-receptor-associated periodic syndrome, unfolded protein response, inisitol-
requiring enzyme 1, lipopolysaccharide, toll-like receptor 4, microRNA-146a, microRNA-155, autoinflammation
INTRODUCTION
Tumor necrosis factor (TNF)-receptor-associated periodic fever 
syndrome (TRAPS) is a rare monogenic autoinflammatory disor-
der characterized by recurrent attacks of fever and inflammation, 
predominantly affecting fibroblast-rich tissues such as serosal 
surfaces, synovial joints, and the deep dermis of the skin (1). 
The disease is both clinically and genetically heterogeneous, with 
over 140 mutations reported to date (2). Likewise, a number of 
molecular mechanisms have been implicated in the pathogenesis 
of TRAPS, including abnormal TNF-receptor 1 (TNFR1) recep-
tor cleavage (3), ligand-independent activation of mutant TNFR1 
(4–6), activation of nuclear factor kappa B (NF-κB)/mitogen-
activated protein kinase (6–10), generation of mitochondrial 
reactive oxygen species (7, 11), and TNFR1 misfolding and reten-
tion within the endoplasmic reticulum (ER), leading to activation 
of the unfolded protein response (UPR) (7). This latter cellular 
stress response appears to be limited to selective activation of the 
ER-associated endonuclease, inositol-requiring enzyme 1 (IRE1) 
(8, 12); however, this activation can have significant proinflam-
matory effects as shown by Martinon et al. They demonstrated 
that lipopolysaccharide (LPS) can activate IRE1, via the TLR4 
signaling pathway. The spliced X-box binding protein 1 (XBP1) 
transcription factor, generated via activation of IRE1, can sub-
sequently bind to the promoter regions of TNF and interleukin 
(IL)-6 (13). In turn, we have shown that inflammatory cytokines, 
such as TNF, can also activate the IRE1 arm of the UPR resulting 
in synthesis of XBP1s (14). Therefore, in TRAPS patients, the 
coexistence of low-level ER stress, with resultant local production 
of proinflammatory cytokines, can promote chronic activation of 
IRE1, and subsequent heightened responsiveness of TRAPS cells. 
These findings corroborate the observations that TRAPS cells are 
hyperresponsiveness to low-dose LPS, with increased produc-
tion of proinflammatory cytokines, the release of which leads to 
clinical manifestations persisting for periods of weeks to months 
(1, 15, 16).
The traditional role for IRE1, as part of the UPR, relates 
to the endonuclease function of this enzyme and its ability to 
target a variety of mRNA and microRNA (miRs) species, and, 
in this way, limit protein production and help to resolve ER 
stress (17). IRE1 regulates the expression of mRNA, and miRs 
via regulated IRE1-dependent decay (RIDD) (18). In this way, 
IRE1 controls protein exit from the ER, including the levels of 
proteins that go on to be involved in regulation of ER processes, 
at both the genetic and epigenetic level. Control of miRs can 
lead to significant modulation in activity of cellular pathways 
by determining either cell survival or death (19). miRs, which 
are small non-coding RNAs that regulate mRNA expression 
by translational inhibition (20), usually have multiple targets, 
which may be found on the same and/or different molecular 
pathways (20).
The co-expression of miR-155 and miR-146 in human 
monocytes, in response to LPS, was first shown in 2006 (21). 
Despite evidence suggesting both pro- and anti-inflammatory 
actions for miR-155, in different contexts, numerous publica-
tions have demonstrated that both miR-155 and -146a target a 
number of downstream signaling pathways involved in toll-like 
receptor 4 (TLR4)-mediated LPS responses (22, 23), suggesting 
that, collectively, these miRs regulate a negative-feedback loop 
to prevent excessive TLR4 activation. In 2011, Schulte et  al. 
suggested a more refined role for these two miRs (24); they 
used a graded LPS challenge to show that miR-146a was neces-
sary for prevention of TLR4 responses, at sub-inflammatory 
doses of LPS, which might be relevant to maintaining tolerance 
to the host’s own microbiome. On the other hand, miR-155 was 
found to limit TLR4 responses following exposure to higher, 
proinflammatory doses of LPS. Thus, failure to upregulate these 
miRs may lead to chronic hyperresponsiveness of the TLR4 
pathway.
We therefore hypothesized that the intracellular levels of miR-
155 and miR-146a may be reduced in TRAPS cells, possibly due 
to targeted destruction by IRE1. Furthermore, the proinflamma-
tory milieu of TRAPS cells, particularly due to paracrine effects of 
TNF and IL-1β, would facilitate this process. We decided to focus 
on the effects of IL-1β, since this cytokine appears to be critical 
to the disease pathogenesis and clinical manifestations of TRAPS, 
and also because anti-IL-1 therapy is now the treatment of choice 
for this condition (25). Furthermore, we elected to study these 
effects in dermal fibroblast (DF) from three TRAPS patients, who 
harbored three different TNFRSF1A mutations, since many of the 
clinical manifestations of TRAPS are localized to fibroblast-rich 
tissues, and we wanted to show that this is not a mutation-specific 
phenomenon.
MATERIALS AND METHODS
Patients and Cells
Primary DF were obtained by digestion of skin biopsies from 
patients with three different TRAPS mutations; T50M and C88R 
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missense mutations, and a C158delinsYERSSPEAKPSPHPRG 
(c.472 + 1 G > A) splice site mutation in the TNFRSF1A gene. 
Primary DF from six healthy controls were used as controls. 
Healthy and patient derived DF were cultured and passaged in 
the same way, using Dulbecco’s Modified Eagle Medium [Gibco 
(Life Technologies), Paisley, UK] supplemented with fetal bovine 
serum (10%v/v), penicillin–streptomycin (1%v/v), and minimum 
essential medium non-essential amino acids (1% v/v) or Fibroblast 
Cellu tions media (Cambridge Biosciences, Cambridge, UK). 
All cells had a morphology and growth pattern consistent with 
fibroblast cells and expressed fibroblast-specific protein.
Immunofluorescence
Fibroblasts were grown on culture chamber slides (BD 
Biosciences, Bedford, MA, USA). Adherent cells were fixed 
using 4% paraformaldehyde, at 37°C for 30 min and blocked 
using 2% bovine serum albumin or MACS buffer (Miltenyi 
Biotec, Surrey, UK) for 30  min at room temperature (RT, 
21°C). Slides were then incubated with 10 ug/μl of TLR4 and 
TNFR1 primary antibodies (R&D systems, Abingdon, UK) and 
goat IgG isotype controls (gift from Dr. Stephenson) for 1 h. 
Slides were washed three times using 1% phosphate-buffered 
saline, and then incubated with equivalent concentrations 
of secondary antibody [FITC polycloncal rabbit anti-goat 
(Abcam, Nottingham, UK)] for 1 h. Slides were then washed 
(as described previously). Coverslips were mounted, using 
ProLong Diamond anti-fade mountant containing DAPI, and 
visualized using the Carl Zeiss Imager Z1 immunofluorescence 
microscope. Images were captured using the AxioCam MRc5 
camera and AxioVision Rel software, v4.7.
Cell Stimulations with LPS, IL-1β, IL-6,  
and TNF
For all experiments, a total of 1.2 ×  105 cells were seeded in 
12-well culture plates and allowed to adhere overnight. Cells 
were then stimulated with 10.0, 1.0, and 0.1 ng/mL LPS for 6 h 
(HC, n = 6; TRAPS, n = 3). In separate experiments, the HC 
DF were incubated with IL-1β (10 ng/mL), TNF (10 ng/mL), and 
thapsigargin (Tg) (300 nM) with or without the IRE1 inhibitor 
4μ8C (50 µM), for 4 h. Supernatants were collected and stored 
at −80°C for analysis of cytokine secretions. RNA was extracted 
from cells using TRIzol reagent.
RNA Extraction
RNA extraction and in-column DNAse treatment was performed, 
using DirectZOL RNA Miniprep Kit (Zymo Research, Irvine, CA, 
USA) or PureLink RNA Mini Kit (Ambion), according to the 
manufacturers’ protocol.
TaqMan Low-Density Array
RNA-derived cDNA from unstimulated cells was synthesized 
using MegaPlex RT Human Pool A v3.0. Expression of 380 
microRNAs was then quantified using TaqMan Low-Density 
Array Card A. Fold change of expression of individual genes 
was calculated using the ΔΔCt method, normalizing to the 
housekeeping gene U6, and unsupervised hierarchical clustering 
analysis was performed, using Cluster v3.0 and Java Tree View. 
In addition, all miRs increased/decreased more than threefold 
compared with HC were analyzed, using the DIANA miRpath 
bioinformatics platform to identify pathways predicted to be 
regulated by miRs.
TaqMan miR-146a and miR-155 Assays
RNA-derived cDNA was synthesized from 100  ng total RNA, 
using TaqMan miRNA Reverse Transcription Kit (Applied 
Biosystems) according to the manufacturers’ protocol. Individual 
qPCR reactions were performed in duplicate, using MicroAmp 
Optical 96-well reaction plates and the ABI 7500 thermal cycler 
(Applied Biosystems). Expression of the target genes was deter-
mined by the ΔΔCt relative quantification method, normalizing 
to the housekeeping gene, RNU6B.
IL-1β Enzyme-Linked Immunosorbent 
Assays (ELISA)
Interleukin-1β ELISA (Novex, Life Technologies) were used to 
measure levels of the proinflammatory cytokine, IL-1β, in cell 
culture supernatant samples, according to manufacturers’ proto-
col. Absorbance was read at 450 nm (with 570 nm γ-correction) 
using Mirthas LB940 (Berthold Technologies, Bad Wildbad, 
Germany) and MikroWin 2000 analysis software.
Statistical Analyses
Details of different statistical methods and software pack-
ages used are provided under the relevant section headings 
above. For some experiments, due to scarcity of samples, 
analyses for each TRAPS mutation represent the results of a 
single individual, and, therefore, formal tests of statistical sig-
nificance were not significant but do imply trends. Statistical 
significance was determined using a two-way ANOVA Sidak’s 
multiple comparisons test, as indicated in the relevant figure 
legends.
RESULTS
TRAPS DF Have Normal Cell Surface 
Expression of TLR4 but Reduced 
Expression of TNFR1
Healthy human DF regulate inflammatory responses by express-
ing various cell surface receptors, including TLR4 (25); therefore, 
to determine if TRAPS DF also continue to express TLR4 
in vitro, and successfully respond to LPS stimulation, we studied 
the expression of TLR4 on the cell surface in primary DF, from 
HC (n = 3) and also from TRAPS patients, respectively, bearing 
T50M, C88R, and c.472 + 1 slice site TNFRSF1A mutation. Surface 
expression of TLR4 in all three TRAPS DF was comparable with 
HC (Figures 1A–F).
We, and others, have previously shown that the mutated 
TNFR1 species tend to aggregate within the cells and to express 
less TNFR1 on the cell surface (7, 26). To date, only one study 
has reported on TNFR1 expression in primary DF, from TRAPS 
patients bearing the C33Y mutation, which found reduced levels 
FIGURE 1 | Detection of surface toll-like receptor 4 (TLR4) and tumor necrosis factor (TNF)-receptor 1 (TNFR1) on healthy control (HC) and TNF receptor-associated 
periodic fever syndrome (TRAPS) dermal fibroblast (DF) using immunofluorescence. Expression of TLR4 (green) from TRAPS (n = 3) and HC (n = 3) DF (A–F). 
Expression of TNFR1 (green) in TRAPS (n = 3) and HC (n = 3) DF (G–L). DAPI (blue) is used to stain the nucleus. Isotype and no primary antibody controls were all 
negative (data not shown). Each image is representative of three images of one to five cells from a slide of 5 × 103 cells from each TRAPS mutation and three HCs.
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of sTNFR1 and also reduced receptor shedding when compared 
with HC (27, 28). Using immunofluorescence, we also demon-
strated that TNFR1 expression was markedly reduced/absent in 
all DF from the three TRAPS patients compared with cells from 
HC (Figures 1G–L).
Negative Regulation of LPS Signaling by 
miR-146a and miR-155 Is Defective in 
TRAPS DF
miR-146a and miR-155 have been shown to operate at different 
levels of LPS stimulation. miR-146a is active at sub-inflammatory 
FIGURE 2 | MicroRNA (miR)-146a, miR-155 in tumor necrosis factor (TNF) 
receptor-associated periodic fever syndrome (TRAPS) and healthy control 
(HC) dermal fibroblast (DF) following graded lipopolysaccharide (LPS) 
challenge. TRAPS (n = 3) and HC (n = 4) DF miR-146a and miR-155 RNA 
expression (A,B) measured by Taqman qPCR. Data were converted to a 
logarithmic scale base 10. The two-way ANOVA (p = ≤ 0.05) test was used 
to determine statistical significance.
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doses of LPS, thus regulating the threshold of activation, whilst 
miR-155 acts as a “molecular brake” of proinflammatory gene 
expression, once the miR-146a-dependent barrier to LPS-
triggered inflammation has been breached (24). Thus, we used 
a graded LPS challenge (0.1–10.0  ng/L) to study these miR 
responses in DF from TRAPS patients and HC. Neither miR-
146a nor miR-155 levels were increased in TRAPS DF, following 
the graded challenge, even after adding 10 ng/mL of LPS for 6 h 
(Figures 2A,B). This was a consistent observation for all three 
TRAPS mutations. In contrast, HC DF showed a dose-dependent 
increase in both miR-146a and miR-155 (Figures  2A,B). As 
expected, IL-1β levels were significantly higher in DF from 
TRAPS patients challenged with graded LPS (Figure S1 in 
Supplementary Material).
Pre-Treatment with Proinflammatory 
Cytokines Promotes miRNA Dysregulation 
in HC DF
In addition to localized connective tissue manifestations, TRAPS 
is also characterized by systemic inflammatory responses, 
due to the release of the proinflammatory cytokines (1, 9, 29). 
Furthermore, previous work, by our group and others, has 
reported UPR activation in TRAPS, associated with increased 
production of IL-1β (1, 7, 13). Therefore, we postulated that 
miR-155 and miR-146a expression in TRAPS DF may be sup-
pressed by IL-1β. To test this hypothesis, HC DF cells (n = 4) 
were incubated with IL-1β, TNF or Tg, which induces ER stress, 
IRE1 activation, and UPR. In addition, the IRE1 inhibitor, 
4μ8C, was added with Tg and levels of miR-146a, miR-155 were 
measured.
There were no differences found in baseline expression of 
miR-146a and miR-155 between treated and untreated HC DF 
(Figure 3). However, there was a significant reduction of LPS-
induced miR-146a and miR-155 expression in HC DF when pre-
treated with IL-1β, TNF, or Tg, and the effects of Tg were partially 
reversed by addition of 4μ8C. These results suggest, as previously 
demonstrated in the literature, that Tg can activate IRE1, lead to 
UPR activation and IL-1β production. The same effect could also 
be achieved by incubating cells with TNF and IL-1β, which are 
both produced following UPR activation.
Pre-Treatment with 4u8C Reduces 
Proinflammatory Cytokine Production  
in TRAPS DF Stimulated with LPS
To determine whether suppression of the miRs by IL-1β was 
dependent on IRE1 cleavage, HC and TRAPS cells pre-treated 
with 4u8C for 4 h before being stimulated with LPS for 4 h. Levels 
of IL-1β, IL-6, and TNF were increased in HC and significantly 
higher in T50M and C472 TRAPS DF after LPS stimulation 
(Figure  4). Following the 4u8C pre-treatment conditions, HC 
DF proinflammatory cytokine secretion was not altered; however, 
both TRAPS DF genotypes produced less IL-1β, IL-6, and TNF in 
response to LPS, with levels that were more like that of the HC DF 
response. These data are consistent with a model whereby IL-1β 
downregulation of miR-146a and miR-155 is dependent on IRE1 
and leads to increased proinflammatory cytokine production in 
TRAPs but not HC DF.
miR Dysregulation Is IRE1 Dependent and 
Is Present at Baseline in TRAPS DF
To corroborate the reduced cytokine production seen in response 
to IRE1 inhibitor 4u8C, both miR-146a and miR-155 were meas-
ured under the same conditions (Figure 5). Both miRs are elevated 
in HC at both baseline and after LPS stimulation, compared 
with low levels in DF from TRAPS under the same conditions 
(Figure 5). In both T50M and C472 TRAPS DF, concentrations 
of both miRs increase after a pre-treatment with IRE1 inhibitor 
4u8c. This result suggests that IRE1-dependent degradation of 
miR-146a and miR-155 not only results in elevated proinflam-
matory cytokine release (Figure 4) but also can be reversed using 
small molecule inhibitors.
In addition to miR-146a, and miR-155, a number of other 
miRs species appear to have unique expression profiles in the sera 
of patients with TRAPS. Lucherini et al. reported on six miRs 
that were differentially expressed and, in addition, were able to 
discriminate TRAPS patients from HC (30). If IRE activation was 
present in TRAPS DF, which our data suggest is the case, then we 
FIGURE 3 | MicroRNA (miR)-146a and miR-155 expression in healthy control (HC) pre-treated with interleukin (IL)-1β, tumor necrosis factor (TNF), and thapsigargin 
(Tg). Pre-treatment of HC dermal fibroblasts (n = 4) with IL-1β (10 ng/mL), TNF (10 ng/mL), and Tg (300 nM). Expression of miR-146a (upper graph) and miR-155 
(lower graph) was measured by Taqman qPCR, with and without the addition of the inositol-requiring enzyme 1 inhibitor 4u8C (50 µM). The two-way ANOVA 
(p = ≤ 0.05) test was used to determine statistical significance.
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would expect other downstream pathways controlled by IRE1, 
such as RIDD, to also be activated. RIDD has the potential to 
target other miRs that regulate other cellular and inflammatory 
processes. Therefore, we investigated whether global expression 
of miRs in DF might be different between TRAPS patients’ DF and 
HC. We used TaqMan Low-Density Array gene cards to measure 
the expression of 384 miRs in DF from all three TRAPS muta-
tions and from three HC at baseline (Figure S2 in Supplementary 
Material). Full data available from NCBI website accession 
number GSE109363. Unsupervised hierarchical clustering clearly 
separated the miR profile of the TRAPS patients from HC, with 
11 miRs being differentially expressed ≥2 fold in at least 2 of the 
3 TRAPS DF compared with HC. These miRs are implicated 
in several biological pathways, including ubiquitin-mediated 
proteolysis, protein processing in the ER, and mRNA surveil-
lance pathways (Table S1 in Supplementary Material). Thus, 
collectively, our data suggest that miR dysregulation in TRAPS 
DF activates a number of biological pathways, including mRNA 
degradation, which could contribute to the hyperresponsiveness 
to LPS and enhanced proinflammatory cytokine production seen 
in this condition.
DISCUSSION
In this study, we show, for the first time, that TRAPS DF with 
T50M, C472, and C88R mutations in TNFRSF1A are hyper-
responsive to LPS. We were also able to induce a similar 
phenotype in healthy DF following stimulation with IL-1β, 
which was partially reversed using the IRE1 inhibitor 4μ8C. 
In both cases, IRE1 activation was associated with significantly 
reduced levels of miR-146a and miR-155 in the cells under 
study. Finally, we have demonstrated the presence of global 
miR dysregulation in TRAPS patients, which, alongside the 
downregulation of miR-146a and miR-155, contributes to the 
proinflammatory phenotype observed in TRAPS T50M, C472, 
and C88R genotypes.
Lucherini et al. reported a 6-miR signature to be diagnostic 
of TRAPS (30); however, to our knowledge, no studies to date 
have suggested a functional role of miRs in TRAPS pathogenesis. 
Evidence to date unequivocally points toward important role for 
miR-146a in numerous inflammatory diseases (22). In the case of 
miR-155, both pro- and anti-inflammatory functions have been 
reported (31, 32). The expression of miR-155 does increase in a 
FIGURE 4 | Proinflammatory cytokine production in tumor necrosis factor 
(TNF) receptor-associated periodic fever syndrome (TRAPS), and healthy 
control (HC) dermal fibroblast, with and without inositol-requiring enzyme 1 
inhibitor 4u8C. Pre-treatment with 4u8C was followed by a stimulation with 
lipopolysaccharide (LPS) (10 ng/mL) in both TRAPS (n = 2) and HC (n = 6). 
The two-way ANOVA (p = ≤ 0.05) test was used to determine statistical 
significance.
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gradual fashion, similar to most other NF-κB-dependent genes 
in response to environmental stimuli. This may imply a role for 
miR-155 in propagating inflammatory responses, particularly 
since it has been shown to stimulate TNF production by stabiliz-
ing its mRNA (33). Furthermore, miR-155 inhibits the translation 
of the anti-inflammatory molecule, SHIP-1 (31) [reviewed in 
Ref. (22, 34, 35)]. However, at the same time, miR-155 was shown 
to suppress some proinflammatory components of the TLR4 
pathway, such as TAB 2 and IKKε (33, 36), which suggests a 
more complex role for this miR in regulation of the inflammatory 
response. Schulte et al. proposed a scenario whereby, on the one 
hand, miR-155 may induce negative regulation of autocrine sign-
aling whilst, at the same time, promoting paracrine signaling via 
TNF (24). The end result could activate bystander macrophages, 
which is essential to deal with infection, but, at the same time, 
miR-155 may limit the magnitude of the inflammatory response 
by preventing hyper-activation of the TNF-producing cells. Our 
data would support such a model. However, to what extent these 
differential roles of miR-155, or the relationship between miR-
146a and miR-155, contribute to specific disease pathogenesis 
remains to be determined.
Our data also highlight the importance of LPS-
hyperresponsiveness in the pathogenesis of TRAPS T50M, C472, 
and C88R mutations. Our group and others have previously 
reported this phenomenon in TRAPS, as well as in other inflam-
matory diseases (37). We have found equivalent levels of surface 
expression of TLR4 between HC and TRAPS, suggesting that the 
LPS-hyperresponsiveness observed was not mediated by differ-
ences in TLR4 surface expression. Interestingly, TNFR1 knockout 
mice are resistant to LPS-induced shock, and human monocytes 
that are deficient in TLR4 are also resistant to LPS (6, 38). Thus, 
mutant TNFR1 may act in synergy with the TLR4 signaling 
pathway, triggering increased cellular stress, and consequent 
lowering of the activation threshold for TLR4-LPS signaling 
which, in turn, further augments intracellular stress levels in 
DF with T50M, C472, and C88R mutations in TNFRSF1A. In 
addition, LPS is expressed at the cell surface of gram-negative 
bacteria, therefore in the LPS-hyperresponsive state, it may be 
possible for commensal, or subclinical bacterial loads, to trigger 
an inflammatory response.
Although TRAPS is associated with mutations in TNFRSF1A 
it seems that IL-1β is also critical to the disease pathogenesis. 
Previous data published by our group, as well as others, have 
reported high levels of IL-1β in the serum of a number of TRAPS 
patients (9, 39). Furthermore, anti-IL-1 targeted therapy is now 
emerging as the treatment of choice for this condition (1, 40–44). 
Our findings suggest that the role exercised by IL-1β in the patho-
genesis of TRAPS is, in part, due to its ability to downregulate 
miR-146a and miR-155. Furthermore, we propose that the effect 
could be mediated by the IRE1 branch of the UPR, since the 
IRE1 inhibitor 4u8C partially reversed inhibition of these miRs. 
We, and others, have shown that proinflammatory cytokines can 
induce IRE1 activation; for example, it has been shown that both 
IL-1β and IL-6 are able to induce ER stress in pancreatic islet 
cells (45). It is also possible that the endoribonuclease activity 
of IRE1 may only be required for the initiation of IL-1β produc-
tion, after which inflammatory cytokine production is driven by 
the autocrine action of proinflammatory cytokines themselves, 
particularly given that activation of IRE1 is associated with the 
induction of apoptosis and cell death (18). For example, IRE1 
cleaves TRAF2, activating the JNK signaling pathway, which is 
important in NF-κB activation and proinflammatory cytokine 
production (46), and, also, TRAF2 is a recognized target of 
miR-146a (20). Finally, it has been shown that IRE1 and TNFR1 
can combine to form an intracellular molecular complex during 
cellular stress, leading to UPR activation (47). This plethora of 
supporting evidence shows that IRE1 plays a significant and com-
plex role in cellular stress responses, in both health and disease.
Thus, in summary, overall our data suggest a model whereby 
TNFR1 protein misfolding within T50M, C472, and C88R muta-
tions, which previously has been shown to occur in TRAPS cells 
(7, 8) activates the IRE1 branch of the UPR. IRE1 activation leads 
to cleavage of miR-146a and miR-155, and consequently results 
FIGURE 5 | Expression of microRNA (miR)-146a and miR-155 in healthy control (HC) and tumor necrosis factor (TNF) receptor-associated periodic fever syndrome 
(TRAPS) dermal fibroblast (DF) with and without inositol-requiring enzyme 1 inhibitor 4u8C. Expression levels of miR-146a and miR-155 was measured in TRAPS DF 
(n = 2) compared with HC (n = 6). The two-way ANOVA (p = ≤ 0.05) test was used to determine statistical significance.
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in hyperresponsiveness to LPS and increased proinflammatory 
cytokine production, such as IL-1β. Subsequently, the paracrine 
effects of these cytokines as well as the proinflammatory local 
environment observed in TRAPS maintain the UPR activation 
state and degradation of miR-146a and miR-155.
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FIGURE S1 |  Interleukin (IL)-1β secretion after graded lipopolysaccharide 
challenge in dermal fibroblast (DF) from healthy control (HC) and patients with 
tumor necrosis factor (TNF) receptor-associated periodic fever syndrome 
(TRAPS). Levels of IL-1β secretion observed from TRAPS DF (n = 3) compared 
with HC (n = 3). The two-way ANOVA (p = ≤ 0.05) test was used to determine 
statistical significance.
FIGURE S2 |  Global expression of microRNAs (miRNAs) in healthy control 
(HC) and tumor necrosis factor (TNF) receptor-associated periodic fever 
syndrome (TRAPS). Expression levels of selected miRs observed in TRAPS 
dermal fibroblast (n = 3) compared with HC (n = 3). Red indicates higher levels 
of expression, and green indicates lower levels of expression. A section of the 
cluster analysis has been magnified to illustrate areas that were clearly different 
between HC and TRAPS.
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